This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Glare Disability in Healthy Subjects
and you are
between 20 and 40
years old
2
3
This is an advanced phase trial assessing
the effectiveness of the new treatment before being released on the market.
Show me locations

The purpose

The purpose of this study is: I. To measure MP optical density (MPOD) spatial profiles in two groups (experimental and placebo) of 50 subjects each (N = 100), during an L + Z supplementation period of 12 months. II. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will result in significantly improved visual performance under disability glare conditions. III. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will result in significantly reduced photostress recovery times. IV. To test the hypothesis that increases in MP (via 12 mg daily L + Z supplementation) will result in improved contrast enhancement.

Provided treatments

  • : lutein and zeaxanthin supplements
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT00909090. The sponsor of the trial is University of Georgia and it is looking for 100 volunteers for the current phase.
Official trial title:
Effects of Lutein and Zeaxanthin Upon MPOD and Its Effects Upon Glare Disability, Photostress Recovery, and Contrast Enhancement in Healthy Subjects: A Randomized, Double-blind Placebo-controlled Study